Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Pembrolizumab (Keytruda), an immune checkpoint inhibitor, is effective against solid tumors with DNA mismatch repair (MMR) deficiency.
• Solid tumors lacking MMR deficiency are generally less responsive to pembrolizumab.

Purpose of the Study:

• To investigate a novel strategy for enhancing pembrolizumab efficacy in solid tumors.
• To explore the potential of inducing a drug-promoted phenotype mimicking MMR deficiency.

Main Methods:

• Inducing metabolic stress on DNA synthesis in solid tumor cells.
• Evaluating the resulting hypersusceptibility to pembrolizumab treatment.

Main Results:

• A drug-induced phenotype mimicking MMR deficiency was successfully generated in solid tumors.
• This engineered state conferred hypersusceptibility to pembrolizumab.

Conclusions:

• Drug-induced metabolic stress on DNA synthesis can create a state of hypersusceptibility to pembrolizumab.
• Combinations of such drugs with pembrolizumab show promise for universal solid tumor treatment and warrant clinical evaluation.